Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Status:
Active, not recruiting
Trial end date:
2023-06-09
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to determine if treatment with high-dose aflibercept
(HD) at intervals of 12 or 16 weeks provides non-inferior best corrected visual acuity (BCVA)
compared to aflibercept dosed every 8 weeks.
The secondary objectives of the study are as follows:
- To determine the effect of HD vs. aflibercept on anatomic and other visual measures of
response
- To evaluate the safety, immunogenicity, and pharmacokinetics (PK) of aflibercept